DNA mutations shed in blood predicts response to immunotherapy
Blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies...
List view / Grid view
Blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies...
27 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the challenges faced with antibody screening and how the iQue Screener can give an evaluation of cell killing mechanism, screening for immune checkpoint inhibitors and more...
In this application note, IntelliCyt Corporation demonstrate a fast, efficient, radioactivity-free CMC assay with low sample input requirements, enabling miniaturisation to 384-well plates, using the iQue® Screener...
22 September 2017 | By IntelliCyt Corporation
In this webinar, Belen Ybarrondo, Ph.D and Thomas Duensing, Ph.D discuss the need for robust high content tools for current immunotherapeutic approaches, and how IntelliCyt's iQue Screener PLUS can give functional efficacy of immuno-oncology therapies...
Immunotherapy drug candidate could be potent weapon against neuroblastoma and other paediatric malignancies...
Immune cells could help to increase immune activity in vaccines or suppress immune reactions in autoimmune diseases...
Manipulation of the sugar metabolism and associated modulation of the immune system could open up new options for treating specific infectious and also autoimmune diseases...
Scientists have described a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA...
Researcher have shown how a mRNA molecule known as Lethal-7 serves as a molecular control hub to direct the function of cytotoxic T lymphocytes...
A report published has identified the prospects of immunotherapy treatments...
The study demonstrates that tissue-resident and circulating memory T cells cooperate in anti-tumour immunity...
The DFG has agreed to fund the Mainz-based Collaborative Research Center involved in the development of nanomaterials for cancer immunotherapy...
Scientists have armed immune cells with a new surface molecule that causes them to respond aggressively when they encounter a protein that tumours actually use to camouflage themselves from the immune system. Researchers from the Helmholtz Zentrum München and various partners introduced the method in ‘Cancer Research’.
Scientists have created a nanoparticle that carries two different antibodies capable of simultaneously switching off cancer cells’ defensive properties while switching on a robust anti-cancer immune response in mice.
Researchers uncovered a new way to enhance the function of a specific type of immune cell that destroys tumours in multiple myeloma...